Soluble Thrombomodulin and Brain Infarction: Case–Control and Prospective Study

Background and Purpose— Increased soluble thrombomodulin (sTM) concentration has been associated with recurrent coronary events, whereas in one prospective study it predicted fewer first-ever coronary events. One study found no relationship between brain infarction (BI) and sTM levels. Among all subjects of the Étude du Profil Génétique de l’Infarctus Cérébral (GENIC) cohort and those free of previous vascular history, we investigated the relationship between sTM level and BI risk, and among cases, its relationship with BI prognosis. Methods— Patients with BI (n=492) were consecutively recruited from 12 centers. Hospital controls without a history of stroke (n=492) were individually matched for age, sex, and center. Blood samples were collected after hospitalization. Determination of sTM levels was centralized in a single laboratory. Results— Soluble TM concentration significantly increased with age and hypertensive status, but was similar in cases and controls. With analyses restricted to 278 pairs of subjects with no previous vascular history, sTM concentration >59.6 μg/L (second and third tertiles compared with the first) was associated with fewer first-ever BI (adjusted odds ratio of 0.56 (95% CI, 0.35 to 0.89; P =0.014). Among the cases, increased sTM concentration was associated with a higher death rate after a median follow-up of 5.2 (1.4 to 6.4) years. The adjusted hazard ratio per 1 SD of sTM concentration increase (34.2 μg/L) was 1.19 (95% CI, 1.02 to 1.39; P =0.028). Conclusions— Increased sTM concentration may be protective against BI in subjects with no previous vascular disease, whereas it may predict a fatal outcome in patients who have already had a BI. Consequently, sTM levels should be interpreted according to vascular history.

[1]  J. Martí-Fàbregas,et al.  Risk of Ischemic Stroke Associated With Functional Thrombin-Activatable Fibrinolysis Inhibitor Plasma Levels , 2003, Stroke.

[2]  E. Boerwinkle,et al.  Interaction Between Soluble Thrombomodulin and Intercellular Adhesion Molecule-1 in Predicting Risk of Coronary Heart Disease , 2003, Circulation.

[3]  Hugh S Markus,et al.  Markers of endothelial dysfunction in lacunar infarction and ischaemic leukoaraiosis. , 2003, Brain : a journal of neurology.

[4]  G. Hallmans,et al.  Prospective Study on Soluble Thrombomodulin and von Willebrand Factor and the Risk of Ischemic and Hemorrhagic Stroke , 2002, Thrombosis and Haemostasis.

[5]  J. Olivot,et al.  Thrombomodulin Prolongs Thrombin-Induced Extracellular Signal—Regulated Kinase Phosphorylation and Nuclear Retention in Endothelial Cells , 2001, Circulation research.

[6]  Berislav V. Zlokovic,et al.  Anti-Inflammatory, Antithrombotic, and Neuroprotective Effects of Activated Protein C in a Murine Model of Focal Ischemic Stroke , 2001, Circulation.

[7]  L. Bajzar.  Thrombin Activatable Fibrinolysis Inhibitor and an Antifibrinolytic Pathway , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[8]  Blann Ad,et al.  von Willebrand factor and soluble thrombomodulin as predictors of adverse events among subjects with peripheral or coronary atherosclerosis. , 1999 .

[9]  V. Salomaa,et al.  Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atheroscierosis in the Atherosclerosis Risk in Communities (ARIC) Study: a case-cohort study , 1999, The Lancet.

[10]  José A Fernández,et al.  Brain-specific protein C activation during carotid artery occlusion in humans. , 1999, Stroke.

[11]  J. Loscalzo,et al.  Endothelial cells in physiology and in the pathophysiology of vascular disorders. , 1998, Blood.

[12]  S. Schreiber,et al.  Thrombomodulin expression in bovine brain capillaries. Anticoagulant function of the blood-brain barrier, regional differences, and regulatory mechanisms. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[13]  C. McCollum,et al.  Prognostic value of increased soluble thrombomodulin and increased soluble E‐selectin in ischaemic heart disease , 1997, European journal of haematology.

[14]  J. Jansson,et al.  Increased levels of plasma thrombomodulin are associated with vascular and all-cause mortality in patients on long-term anticoagulant treatment. , 1996, European heart journal.

[15]  J. Manson,et al.  Prospective study of endogenous tissue plasminogen activator and risk of stroke , 1994, The Lancet.

[16]  H. Ishii,et al.  Soluble Thrombomodulin Antigen in Conditioned Medium Is Increased by Damage of Endothelial Cells , 1991, Thrombosis and Haemostasis.

[17]  C. Esmon,et al.  Thrombomodulin blocks the ability of thrombin to activate platelets. , 1983, The Journal of biological chemistry.

[18]  C. Esmon,et al.  Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[19]  A. Blann,et al.  von Willebrand factor and soluble thrombomodulin as predictors of adverse events among subjects with peripheral or coronary atherosclerosis. , 1999, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.